NLRP3 and neoplasm: RRx-001 is a theoretically attractive agent to add to radiotherapy and cytotoxic chemotherapy based on a preclinical studies demonstrating several potential anti-tumor mechanisms of action including, anti-angiogenesis, nitric oxide donation and vascular normalization, potentiation of radiation-induced reactive oxygen species, NLRP3 inhibition, repolarization of therapy resistance tumor-associated macrophage (TAM).